1 Medicine, J. H. U. a. Coronavrus Resource Centre, <https://coronavirus.jhu.edu/> (2021).
2 Sadarangani, M., Marchant, A. & Kollmann, T. R. Immunological mechanisms of vaccine-induced protection against COVID-19 in humans. Nature reviews. Immunology, doi:10.1038/s41577-021-00578-z (2021).
3 Sadoff, J. et al. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. The New England journal of medicine 384, 2187-2201, doi:10.1056/NEJMoa2101544 (2021).
4 Ramasamy, M. N. et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet 396, 1979-1993, doi:10.1016/S0140-6736(20)32466-1 (2021).
5 Logunov, D. Y. et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet 397, 671-681, doi:10.1016/S0140-6736(21)00234-8 (2021).
6 Logunov, D. Y. et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet 396, 887-897, doi:10.1016/S0140-6736(20)31866-3 (2020).
7 Jones, I. & Roy, P. Sputnik V COVID-19 vaccine candidate appears safe and effective. Lancet 397, 642-643, doi:10.1016/S0140-6736(21)00191-4 (2021).
8 Voysey, M. et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 397, 99-111, doi:10.1016/S0140-6736(20)32661-1 (2021).
9 Fund, R. D. I. SPUTNIK V AUTHORIZED IN 30 COUNTRIES, <https://sputnikvaccine.com/newsroom/pressreleases/sputnik-v-authorized-in-30-countries/> (2021).
10 Fund, R. D. I. Sputnik Light Covid Vaccine Shows 78.6-83.7% Efficacy Among Elderly: Russian Maker, <https://rdif.ru/Eng_fullNews/6969/> (2021).
11 Zhang, S. et al. Seroprevalence of neutralizing antibodies to human adenoviruses type-5 and type-26 and chimpanzee adenovirus type-68 in healthy Chinese adults. Journal of medical virology 85, 1077-1084, doi:10.1002/jmv.23546 (2013).
12 Barouch, D. H. et al. International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. Vaccine 29, 5203-5209, doi:10.1016/j.vaccine.2011.05.025 (2011).
13 Jeewandara, C. et al. Immune responses to a single dose of the AZD1222/Covishield vaccine in health care workers. Nat Commun 12, 4617, doi:10.1038/s41467-021-24579-7 (2021).
14 Jeewandara, C. et al. Antibody and T cell responses to a single dose of the AZD1222/Covishield vaccine in previously SARS-CoV-2 infected and naïve health care workers in Sri Lanka. medRxiv, 2021.2004.2009.21255194, doi:10.1101/2021.04.09.21255194 (2021).
15 Tan, C. W. et al. A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction. Nature biotechnology 38, 1073-1078, doi:10.1038/s41587-020-0631-z (2020).
16 Jeewandara, C. et al. SARS-CoV-2 neutralizing antibodies in patients with varying severity of acute COVID-19 illness. Sci Rep 11, 2062, doi:10.1038/s41598-021-81629-2 (2021).
17 Jeewandara, C. et al. Antibody and T cell responses to Sinopharm/BBIBP-CorV in naïve and previously infected individuals in Sri Lanka. medRxiv, 2021.2007.2015.21260621, doi:10.1101/2021.07.15.21260621 (2021).
18 Townsend, A. et al. A haemagglutination test for rapid detection of antibodies to SARS-CoV-2. Nature Communications, 2020.2010.2002.20205831, doi:10.1101/2020.10.02.20205831 (2020).
19 Kamaladasa, A. et al. Comparison of two assays to detect IgG antibodies to the receptor binding domain of the SARSCoV2 as a surrogate marker for assessing neutralizing antibodies in COVID-19 patients. Int J Infect Dis, doi:10.1016/j.ijid.2021.06.031 (2021).
20 Bosnjak, B. et al. Low serum neutralizing anti-SARS-CoV-2 S antibody levels in mildly affected COVID-19 convalescent patients revealed by two different detection methods. Cellular & molecular immunology 18, 936-944, doi:10.1038/s41423-020-00573-9 (2021).
21 Khoury, D. S. et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nature medicine 27, 1205-1211, doi:10.1038/s41591-021-01377-8 (2021).
22 Bergwerk, M. et al. Covid-19 Breakthrough Infections in Vaccinated Health Care Workers. The New England journal of medicine, doi:10.1056/NEJMoa2109072 (2021).
23 Voysey, M. et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet 397, 881-891, doi:10.1016/S0140-6736(21)00432-3 (2021).
24 Lopez Bernal, J. et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. The New England journal of medicine, doi:10.1056/NEJMoa2108891 (2021).
25 Coughlan, L. Factors Which Contribute to the Immunogenicity of Non-replicating Adenoviral Vectored Vaccines. Frontiers in immunology 11, 909, doi:10.3389/fimmu.2020.00909 (2020).
26 Madhi, S. A. et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. The New England journal of medicine 384, 1885-1898, doi:10.1056/NEJMoa2102214 (2021).
27 Sette, A. & Crotty, S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell 184, 861-880, doi:10.1016/j.cell.2021.01.007 (2021).
28 Ewer, K. J. et al. T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. Nature medicine 27, 270-278, doi:10.1038/s41591-020-01194-5 (2021).
29 Galipeau, Y., Greig, M., Liu, G., Driedger, M. & Langlois, M. A. Humoral Responses and Serological Assays in SARS-CoV-2 Infections. Frontiers in immunology 11, 610688, doi:10.3389/fimmu.2020.610688 (2020).
30 Zhou, D. et al. Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient. Nat Struct Mol Biol 27, 950-958, doi:10.1038/s41594-020-0480-y (2020).
31 Malavige, G. N. et al. Viral load, clinical disease severity and cellular immune responses in primary varicella zoster virus infection in Sri Lanka. PloS one 3, e3789 (2008).
32 Peng, Y. et al. Broad and strong memory CD4(+) and CD8(+) T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19. Nature immunology 21, 1336-1345, doi:10.1038/s41590-020-0782-6 (2020).